| GR00053-A | 1746 | NM_004405 | DLX2 | np | sp | none | | no | | Genome stability | A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. | Paulsen et al. | 2009 | 19647519 | Cell line | HeLa | gamma-H2AX phosphorylation and DNA content | Fluorescence | siARRAY human genome siRNA library | Genome-wide | siRNA | p-value | Complex criteria | Confidence groupings from 4 to 1 (highest level of confidence in group 4) | GR00054-A | 1746 | NM_004405 | DLX2 | np | 0.931 | none | | no | | Combinatorial effect with paclitaxel | Synthetic lethal screen identification of chemosensitizer loci in cancer cells. | Whitehurst et al. | 2007 | 17429401 | Cell line | NCI-H1155 | Viability (synthetic lethal) | ATP level | # G-005000-01 | Genome-wide | siRNA | Paclitaxel/control ratio | Complex criteria | Additional information about 87 high-confidence hits | GR00056-A | 1746 | NM_004405 | DLX2 | np | 0.795 | none | | no | | Melanogenesis | Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. | Ganesan et al. | 2008 | 19057677 | Cell line | MNT-1 | Melanin protein expression and viability | Absorbance and luminescence | rp | Genome-wide | siRNA | Normalized absorbance ratio | > 2 standard deviations below mean | Additional information about a secondary screen (retest to determine false-positive rate) | GR00057-A-1 | 1746 | NM_004405 | DLX2 | M-011846-00 | -0.38 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 1746 | NM_004405 | DLX2 | M-011846-00 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00095-A | 1746 | L07919 | DLX2 | np | np | none | | | | p53 pathway components | A large-scale RNAi screen in human cells identifies new components of the p53 pathway | Berns et al. | 2004 | 15042092 | Cell line | BJ-TERT-tsLT fibroblasts | Proliferation | Colony-forming cell assay | Nki library | Genome-wide | shRNA | np | np | | GR00123-A | 1746 | L07919 | DLX2 | 109862, 109863, 109861 | np | none | | | | Combinatorial effect with nutlin-3 | An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors | Brummelkamp et al. | 2006 | 16474381 | Cell line | MCF-7 | Viability | Fluoresence | Nki library | Genome-wide | shRNA | log2 ratio | np | | GR00149-A-1 | 1746 | 1746 | DLX2 | 5079 | 9.67 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1746 | 1746 | DLX2 | 5079 | -3.41 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1746 | 1746 | DLX2 | 5171 | -5.27 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1746 | 1746 | DLX2 | 5171 | 13.35 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1746 | 1746 | DLX2 | 5262 | -5.49 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1746 | 1746 | DLX2 | 5262 | -46.11 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1746 | 1746 | DLX2 | 107401 | 25.21 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 1746 | 1746 | DLX2 | 107401 | 10.37 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00180-A-1 | 1746 | 1746 | DLX2 | PL-50008 | 0.898 | none | | no | | Hepatitis C virus replication (1) | A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. | Tai et al. | 2009 | 19286138 | Cell line | Huh7/Rep-Feo | HCV replicon RNA copy number | Luminescence | siARRAY Human Genome siRNA Library | Genome-wide | siRNA | q-value | Complex criteria | | GR00184-A-1 | 1746 | NM_004405 | DLX2 | M-011846-00 | -1.90250269321674 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00197-A-1 | 1746 | 1746 | DLX2 | M-011846-00 | -1.467817362 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | | 1746 | | DLX2 | np | np | Decreased viability in glioblastoma multiforme (GBM) lineage | | no | GBM: no filter, 2nd best | | | | | | | | | | | | | | | | GR00236-A-1 | 1746 | 1746 | DLX2 | M-011846-00 | 1.59333886728349 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00240-S-1 | 1746 | NM_004405 | DLX2 | M-011846-00 | 0.8 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 1746 | NM_004405 | DLX2 | M-011846-00 | -0.42 | none | | no | Z-score 0.4585 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00242-A-1 | 1746 | NM_004405 | DLX2 | np | sp | none | | no | | Selective autophagy regulation (1) | Image-based genome-wide siRNA screen identifies selective autophagy factors. | Orvedahl et al. | 2011 | 22020285 | Cell line | HeLa/GFP-LC3 | Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression | Fluorescence | siGenome | Genome-wide | siRNA | Z-score | Complex criteria | | GR00247-A-1 | 1746 | | DLX2 | np | sp | none | | | rank: 17676 | Regulation of FOXO1 nuclear localization (1) | Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. | Senapedis et al. | 2011 | 21460183 | Cell line | U2OS | EGFP-FOXO1a protein expression and DNA content | Fluorescence | Human Genome library | Genome-wide | siRNA | Complex, sp | Complex criteria | | GR00249-S | 1746 | 1746 | DLX2 | J-011846-05 | -0.17816 | none | | no | number of cells compared to control (%): 83.62 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1746 | 1746 | DLX2 | M-011846-01 | -0.60033 | none | | no | number of cells compared to control (%): 84.24 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1746 | 1746 | DLX2 | s4137 | 0.17746 | none | | no | number of cells compared to control (%): 97.59 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1746 | 1746 | DLX2 | s4138 | 0.54635 | none | | no | number of cells compared to control (%): 73.80 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 1746 | 1746 | DLX2 | s4139 | -0.16139 | none | | no | number of cells compared to control (%): 65.32 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00253-A | 1746 | NM_004405 | DLX2 | np | 0.13 | none | | | | hepcidin regulation | Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. | Mleczko-Sanecka et al. | 2014 | 24385536 | Cell line | Huh7 | hepcidin::fluc mRNA expression | Luminescence | siGenome siARRAY SMARTpool | Genome-wide | siRNA | Z-score | > | Cutoff < | GR00255-A-1 | 1746 | 1746 | DLX2 | TRCN0000013763, TRCN0000013764, TRCN0000013766, TRCN0000013767 | 0.070829499 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 1746 | 1746 | DLX2 | TRCN0000013763, TRCN0000013764, TRCN0000013766, TRCN0000013767 | 0.267909407 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 1746 | 1746 | DLX2 | TRCN0000013763, TRCN0000013764, TRCN0000013766, TRCN0000013767 | 0.180054636 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 1746 | 1746 | DLX2 | TRCN0000013763, TRCN0000013764, TRCN0000013766, TRCN0000013767 | 0.121759688 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 1746 | 1746 | DLX2 | TRCN0000013763, TRCN0000013764, TRCN0000013766, TRCN0000013767 | -0.148676905 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00293-A | 1746 | | DLX2 | np | -0.94 | none | | | | Combinatorial effect with paclitaxel | Mechanisms Promoting Escape from Mitotic Stress−Induced Tumor Cell Death | Sinnott et al. | 2014 | 24860162 | Cell line | HCC366 | Viability | Luminescence | Thermo-Fisher | Genome-wide | siRNA | Z-score | < -2.5 | Final hits according to the author are indicated in the comment. | GR00300-A | 1746 | | DLX2 | TRCN0000013763, TRCN0000013767, TRCN0000013766, TRCN0000013764 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00303-A | 1746 | NM_004405 | DLX2 | np | 0.18 | none | | | | Clear cell renal cell carcinoma (ccRCC) survival regulation | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target | Gerlinger et al. | 2012 | 22362593 | Cell line | VHL-deficient RCC4 | Proliferation and Viability | Fluorescence | np | Genome-wide | siRNA | Z-score | < | In the phenotype data duplicates were in the original document, which have been removed. | GR00310-A-1 | 1746 | 1746 | DLX2 | np | 0.86 | none | | | | Sindbis virus (SINV) infection (1) | Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry | Ooi et al. | 2013 | 24367265 | Cell line | U2OS | Sindbis virus (SINV) reporter | Luminescence | Ambion Silencer V3 | Genome-wide | siRNA | Z-score | < -3 OR > 2 | | | 1746 | 1746 | DLX2 | np | 28.2 | none | | | 55,3% viability | | | | | | | | | | | | | | | | GR00313-A | 1746 | NM_004405 | DLX2 | np | -0.95 | none | | | | TNF-alpha pathway regulation | A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. | Nickles et al. | 2012 | 22733992 | Cell line | HEK293T | NFkappaB pathway reporter | Luminescence | Qiagen | Genome-wide | siRNA | Z-score | < | Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. | GR00318-A | 1746 | 1746 | DLX2 | np | 0.879 | none | | | siRNA set: druggable genome | Huntingtin toxicity | A Genome-Scale RNA–Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington’s Disease | Miller et al. | 2012 | 23209424 | Cell line | HEK293T | Caspase 3/7 activity | Fluorescence | Dharmacon | Selected genes | siRNA | Sum of normalized caspase 3/7 activity mean and standard error | < 0.683 | HEK293T cells were cotransfected with mutant Huntingtin fused to GFP (Htt1-558141Q-GFP). | GR00327-A | 1746 | 1746 | ABCA5 | CLL-H-000136 | 0.6602468597907232 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1746 | 1746 | ABCA5 | CLL-H-000137 | 0.4609513741858368 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1746 | 1746 | ABCA5 | CLL-H-000140 | 0.15941728004396974 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1746 | 1746 | ABCA5 | CLL-H-000141 | -0.11456882426338398 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1746 | 1746 | ABCA5 | CLL-H-000139 | -0.035594687068521466 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00327-A | 1746 | 1746 | ABCA5 | CLL-H-000138 | 0.37192608042976477 | none | | | | Tumor formation | An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation | Wolf et al. | 2013 | 24292671 | Cell line | SUM-149 | shRNA abundance | Next-generation sequencing | Decipher library module 1 | Selected genes | shRNA | Z-score | > 2.24 | Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. | GR00343-S | 1746 | 1746 | DLX2 | TRCN0000013767 | 0.3149999999999995 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 1746 | 1746 | DLX2 | TRCN0000013766 | -0.6699999999999982 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 1746 | 1746 | DLX2 | TRCN0000013763 | -0.9324999999999992 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 1746 | 1746 | DLX2 | TRCN0000013764 | 0.942499999999999 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00360-A-1 | 1746 | ENSG00000115844 | DLX2 | 114415 | 0.9287500000000001 | Mildly decreased CFP-tsO45G cell surface transport | | | | Secretory transport (1) | Genome-wide RNAi screening identifies human proteins with a regulatory function in the early secretory pathway | Simpson et al. | 2012 | 22660414 | Cell line | HeLa Kyoto | CFP-tsO45G cell surface transport | Fluorescence | Ambion | Genome-wide | siRNA | Deviation score | < - 1 OR > 0.75 (mild: 0.75 - 1.0; strong: > 1.0) | For validation screen see Secretory transport (2). | GR00368-A | 1746 | 1746 | DLX2 | | 0.84 | Decreased viability ratio | | | wt viability: 0,86 | Combinatorial effect with E-Cadherin | Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells | Telford et al. | 2015 | 25777964 | Cell line | MCF10A | Viability (synthetic lethal) | Luminescence | Dharmacon | Genome-wide | siRNA | CDH1(-/-)/wt viability ratio | < | MCF10A wild type viability higher-or-equal to 50% was considered as additional cutoff (values noted in "comment" section). | | 1746 | 1746 | DLX2 | | -0.019999999999999997 | none | | | | | | | | | | | | | | | | | | | GR00371-A-1 | 1746 | 1746 | DLX2 | | 0.123586335272 | none | | | Ambion | Nanog expression in absence of bFGF and TGFbeta | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-2 | 1746 | DLX2 | 1746 | | 0.0424821965357 | none | | | Ambion | Nanog expression in presence of TGFbeta inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-3 | 1746 | 1746 | DLX2 | | -0.022989949936 | none | | | Ambion | Nanog expression in presence of MEK inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-4 | 1746 | 1746 | DLX2 | | -0.18118901414 | none | | | Ambion | Nanog expression in presence of PI3K inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-5 | 1746 | 1746 | DLX2 | | 0.33638730438 | none | | | Ambion | Nanog expression in presence of retinoic acid | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00376-A-1 | 1746 | 1746 | DLX2 | | 0.282646985 | none | | | | Mitigators of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID | GR00376-A-2 | 1746 | 1746 | DLX2 | | 0.023983483 | none | | | | Sensitizers of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID | GR00378-A | 1746 | | DLX2 | | -0.091643177 | none | | | | Poliovirus vaccine production | Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game | van der Sanden et al. | 2015 | 26581994 | Cell line | HEp-2C | Infection with Attenuated Poliovirus | ELISA | Dharmacon | Genome-wide | siRNA | Z-score | > | For infection, a single lot of the attenuated Sabin type 2 poliovirus was used for the screen. Gene IDs were not provided, only the gene name/symbol | | 1746 | NM_004405 | DLX2 | | 42.962 | none | | | | | | | | | | | | | | | | | | | GR00386-A-1 | 1746 | 1746 | DLX2 | | 56.4422114638471 | Decreased viability | | | | NOD2 stimulation by MDP | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | Viability | Luminescence | Dharmacon | Genome-wide | siRNA | Percentage growth | Decreased: <70, increased: >120 | Reagent IDs not provided | GR00386-A-2 | 1746 | 1746 | DLX2 | | -58.2 | none | | | | MDP-induced IL-8 secretion | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | IL-8 secretion | ELISA | Dharmacon | Genome-wide | siRNA | Percent inhibition of IL-8 secretion | Increased: <-300, Decreased: >60 | Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |